Adaptive Radiation Therapy Increases Safety and Preserves Quality of Life, Says Study
For patients with recurrent retroperitoneal sarcomas that cannot be treated surgically, treatment choices are limited. These tumors can grow quite large in the abdomen adjacent to vital organs or enmeshed within the bowel.
Clinical Scorecard: Adaptive Radiation Therapy Increases Safety and Preserves Quality of Life, Says Study
At a Glance
Category Detail
Condition Recurrent retroperitoneal sarcomas Key Mechanisms CT adaptive stereotactic body radiation therapy (CTA-SBRT) allows for real-time treatment plan adjustments. Target Population Patients with recurrent retroperitoneal sarcomas that cannot be treated surgically. Care Setting Fox Chase Cancer Center
Key Highlights
Radiation to the small intestine reduced by 21% while tumor doses increased by 7.7%. No serious complications or emergency surgeries reported. Patients maintained normal bowel and bladder function. Real-time re-optimization of treatment plans for each session. Adaptive therapy expands treatment options across various cancer types. Guideline-Based Recommendations
Diagnosis
Consider adaptive radiation therapy for patients with recurrent sarcomas. Management
Utilize CTA-SBRT for repeat radiation treatments. Monitoring & Follow-up
Monitor patient response and adjust treatment plans in real-time. Risks
Assess potential risks of radiation exposure to healthy tissues. Patient & Prescribing Data
Patients with recurrent sarcomas and other hard-to-treat cancers.
Adaptive radiation therapy aims for long-term disease control rather than short-term palliative care.
Clinical Best Practices
Implement real-time imaging and AI software for treatment planning. Cross-train radiation oncologists to offer adaptive radiation therapy. Incorporate patient anatomy changes into treatment planning. References
